The Effect of Tetrahydrocannabinol on Ocular Hemodynamics in Healthy Subjects

Inclusion Criteria: * Men and women aged between 18 and 35 years * Normal ophthalmic findings * Ametropia ≤ 6 diopters * Normal findings in the medical history and physical examination including ECG unless the investigator considers an abnormality to be clinically irrelevant * Normal findings in the laboratory testing unless the investigator considers an abnormality to be clinically irrelevant * Nonsmokers Exclusion Criteria: * Regular use of medication, abuse of alcoholic beverages or drugs * History of drug or alcohol abuse * Psychiatric disorders in the medical history * Risk for drug dependence as evaluated by a psychiatrist * Participation in a clinical trial in the 3 weeks preceding the study * Positive urine drug test at the screening examination or on the study days * Positive alcohol breath test at the screening examination or on the study days * Regular consumption of cannabis and inability to not consume cannabis during the study period * Treatment in the previous 3 weeks with any drug (except intake of oral contraceptives) * Symptoms of a clinically relevant illness in the 3 weeks before the first study day * History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs * Blood donation during the previous 3 weeks * Known hypersensitivity to any of the components of the IMP under investigation or other study medication * History or family history of epilepsy * Pregnant or breast-feeding women * Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception (oral contraceptives, intra-uterine device, contraceptive implant or condoms)